Allergan plc (NYSE:AGN) hit a new 52-week low on Friday . The stock traded as low as $119.25 and last traded at $119.71, with a volume of 7412 shares. The stock had previously closed at $121.00.
AGN has been the subject of a number of recent analyst reports. ValuEngine downgraded shares of Allergan from a “sell” rating to a “strong sell” rating in a research report on Tuesday. Royal Bank of Canada set a $165.00 price objective on shares of Allergan and gave the company a “hold” rating in a research report on Monday, March 25th. Cantor Fitzgerald reduced their price objective on shares of Allergan from $180.00 to $125.00 and set a “neutral” rating for the company in a research report on Wednesday. Wells Fargo & Co reduced their price objective on shares of Allergan from $189.00 to $188.00 and set an “outperform” rating for the company in a research report on Wednesday, May 8th. Finally, Raymond James reduced their price objective on shares of Allergan from $181.00 to $166.00 and set an “outperform” rating for the company in a research report on Thursday, May 9th. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $175.30.
The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.60 and a current ratio of 0.71. The stock has a market cap of $39.21 billion, a PE ratio of 7.08, a P/E/G ratio of 1.12 and a beta of 1.39.
The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Tuesday, May 14th will be given a dividend of $0.74 per share. The ex-dividend date is Monday, May 13th. This represents a $2.96 dividend on an annualized basis and a dividend yield of 2.51%. Allergan’s payout ratio is 17.74%.
Several hedge funds have recently bought and sold shares of the company. Advisors Asset Management Inc. increased its stake in shares of Allergan by 10.7% during the 4th quarter. Advisors Asset Management Inc. now owns 5,856 shares of the company’s stock worth $783,000 after purchasing an additional 565 shares in the last quarter. Dupont Capital Management Corp increased its stake in shares of Allergan by 29.3% during the 4th quarter. Dupont Capital Management Corp now owns 4,283 shares of the company’s stock worth $572,000 after purchasing an additional 970 shares in the last quarter. Chicago Equity Partners LLC purchased a new position in shares of Allergan during the 4th quarter worth approximately $355,000. Daiwa Securities Group Inc. increased its stake in shares of Allergan by 2.0% during the 4th quarter. Daiwa Securities Group Inc. now owns 12,882 shares of the company’s stock worth $1,722,000 after purchasing an additional 250 shares in the last quarter. Finally, Victory Capital Management Inc. increased its stake in shares of Allergan by 12.2% during the 4th quarter. Victory Capital Management Inc. now owns 492,014 shares of the company’s stock worth $65,763,000 after purchasing an additional 53,413 shares in the last quarter. Institutional investors own 80.29% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Allergan (NYSE:AGN) Hits New 52-Week Low at $119.25” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2019/06/14/allergan-nyseagn-hits-new-52-week-low-at-119-25.html.
Allergan Company Profile (NYSE:AGN)
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Story: How to Use a Moving Average for Trading
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.